Ronald M. Witteles

Advanced Heart Failure and Transplant Cardiology | Cardiology
300 Pasteur Dr
Stanford, CA 94305

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 160 publications

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.

Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.

Journal: Future cardiology
Published: August 03, 2026

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: July 09, 2026

Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.

Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.

Journal: Journal of the American College of Cardiology
Published: June 22, 2026

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

Journal: Journal of the American College of Cardiology
Published: June 22, 2026

Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality.

Delayed Diagnosis of Transthyretin Cardiac Amyloidosis Is Associated With Heart Failure Hospitalizations and Mortality.

Journal: JACC. Advances
Published: June 16, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure
Published: May 08, 2026

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.

Journal: Journal of cardiac failure
Published: May 08, 2026

Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: Mechanisms, Prognostic Implications, and Management.

Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy: Mechanisms, Prognostic Implications, and Management.

Journal: Heart rhythm
Published: April 30, 2026

Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population.

Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population.

Journal: JAMA cardiology
Published: April 29, 2026

Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.

Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.

Journal: Stem cell research
Published: April 10, 2026

The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM.

The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM.

Journal: JACC. CardioOncology
Published: April 08, 2026

Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension.

Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension.

Journal: Cardiology and therapy
Published: January 29, 2026
Showing 1-12 of 160

Last Updated: 09/26/2026